Types of Registered Studies
ClinicalTrials.gov
This table shows the number and types of studies that are registered and for which results are available on ClinicalTrials.gov.
* A study may include more than one type of intervention (that is, a single study may be counted more than once). Because of this, the sum of counts by type of intervention do not equal the total number of interventional studies.
** A total of 539 applicable device clinical trials were submitted as "delayed posting" under the Food and Drug Administration Amendments Act of 2007 (FDAAA). That is, the Responsible Party has indicated that such a trial includes a device not previously approved or cleared by the U.S. FDA for any use. These are not included in the count of trials with at least one device.
*** Results are only required to be submitted for certain studies. For example, results submission is generally not required for observational studies; trials completed before 2008; and trials that include drugs, biologics, or devices not previously approved by the U.S. FDA for any use.
N/A = not applicable
See locations of the recruiting studies here, locations of registered studies here, and numbers of registered studies over time here.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
